The U.S. Food and Drug Administration said on Thursday its preliminary review did not find evidence that weight-loss drugs such as Novo Nordisk's NOVOb.CO Wegovy were tied to suicidal thoughts and the agency will continue to study the issue.
Still, the FDA, which has listed suicidal thoughts as a potential safety signal for such drugs, said it could not definitively rule out that a small risk may exist due to the limited data available.